Health
LT3001 DEMONSTRATES FUNCTIONAL IMPROVEMENTS IN PATIENTS WITH DISABLING ACUTE ISCHEMIC STROKE
Lumosa Therapeutics (Lumosa; 6535.TWO) today announced positive results from two independent Phase 2 clinical trials with its novel stroke drug LT3001 (Odatroltide). LT3001 is a first-in-class dual-functional therapy that combines safe reperfusion with direct neuroprotection, addressing key limitations of current acute ischemic stroke treatments. These data revealed that LT3001 delivers meaningful functional improvements in patients suffering from disabling acute ischemic stroke (AIS), offering
About this update from Lumosa Therapeutics Co Ltd
[{"type":"list","items":[{"val":[{"type":"text","content":"Breakthrough Phase 2 Trial Results Show Promise for Patients Ineligible for Standard Reperfusion Therapies","length":106,"tagName":"p"}]},{"val":[{"type":"text","content":"Data Presented at International Stroke Conference","length":49,"tagName":"p"}]},{"val":[{"type":"text","content":"Data Show That LT3001 Delivers Meaningful Functional Improvements in Patients Suffering from Disabling Acute Ischemic Stroke (AIS)","length":130,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":285,"olType":false},{"type":"text","content":"TAIPEI, Feb. 6, 2026 /PRNewswire/ -- Lumosa Therapeutics (Lumosa; 6535.TWO) today announced positive results from two independent Phase 2 clinical trials with its novel stroke drug LT3001 (Odatroltide). LT3001 is a first-in-class dual-functional therapy that combines safe reperfusion with direct neuroprotection, addressing key limitations of current acute ischemic stroke treatments. These data revealed that LT3001 delivers meaningful functional improvements in patients suffering from disabling acute ischemic stroke (AIS), offering new hope for those who cannot receive standard reperfusion treatments. These data were reported here today at the International Stroke Conference in New Orleans.","length":698,"tagName":"p"},{"type":"text","content":"The groundbreaking results demonstrate LT3001's potential to transform outcomes for stroke patients facing limited therapeutic options. The novel therapeutic agent, which enhances endogenous fibrinolysis and scavenges harmful free radicals, showed particularly impressive results in moderate stroke patients with disabling symptoms. In the LT3001-202 trial conducted in China, moderate stroke patients with disabling symptoms treated with LT3001 achieved 8% and 13% improvements in modified Rankin Scale (mRS) scores of 0-1 and 0-2 respectively, compared to placebo.","length":570,"tagName":"p"},{"type":"text","content":"Most remarkably, LT3001 showed improvement in functional outcomes in LAA and mismatch-positive populations. In Study 202, LAA patients (n=169) showed an 11% improvement in mRS 0–2 and a 9% gain in mRS 0–1. Study 205 validated these signals via imaging assisted selection, with mismatch-positive patients achieving a 10% absolute improvement in mRS 0–2. These clinical advances could restore independence to thousands of...